LL-37
Also called Cathelicidin, CAP-18, hCAP18
Topical (on the skin)Human study reference
Research reference
Human study
HEAL LL-37 topical ulcer trial
Topical 0.5 or 1.6 mg/mL twice weekly alongside compression
13 weeks, followed by 16 weeks of observation
Mahlapuu et al., Wound Repair and Regeneration (2021) ↗When results may show
- When change was measured
- The overall study did not show a significant healing difference versus placebo. A large-wound subgroup finding was exploratory.
- When to assess
- 13 weeks, followed by 16 weeks of observation
- Conditions and limitations
- 148 analyzed adults with hard-to-heal venous leg ulcers. Topical wound concentrations are not systemic injection doses. No general antimicrobial or under-the-skin starter is established.
- When to stop
- The measured study window is not a validated personal quit rule. Do not increase or prolong exposure because an expected result is absent; severe or persistent reactions need prompt clinical review.
Research timing is descriptive, not a promise or personal instruction. A severe or persistent reaction needs prompt clinical review. This is not medical advice.
Modelled level — every other day
1× is the peak after a single dose.
- Steady-state peak
- 1.00× single dose
- Time to steady state
- 3hours
- Administrations
- 3.5/ week
Read off the modelled curve, not an even-interval formula
About five half-lives
Averaged over two weeks
Where these numbers come from
- Mahlapuu et al., Wound Repair and Regeneration (2021)Topical wound concentrations are not systemic injection doses. No general antimicrobial or under-the-skin starter is established.